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Abstract
The default causal SNP effect size prior in Bayesian fine-mapping studies is usually the Normal
distribution. This choice is often based on computational convenience, rather than evidence that
it is the most suitable prior distribution. The choice of prior is important because previous studies
have shown considerable sensitivity of causal SNP Bayes factors to the form of the prior. In some
well-studied diseases there are now considerable numbers of GWAS top hits along with estimates
of the number of yet-to-be-discovered causal SNPs. We show how the effect sizes of the top hits
and estimates of the number of yet-to-be-discovered causal SNPs can be used to choose between
the Laplace and Normal priors, to estimate the prior parameters and to quantify the uncertainty
in this estimation. The methodology can readily be applied to other priors. We show that the top
hits available from breast cancer GWAS provide overwhelming support for the Laplace over the
Normal prior which has important consequences for variant prioritisation. This work in this paper
enables practitioners to derive more objective priors than are currently being employed and could
lead to prioritisation of different variants.
Data Sharing Statement
Data sharing is not applicable to this article as no new data were created or analyzed in this study.
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Introduction
Fine-mapping is the process of assigning probabilities of causation to candidate variants identi-
fied through genome-wide association studies (GWAS). The ultimate aim is to identify the target
gene whose function is altered by the variants, taking into account the functional annotation of
the individual variants [Spain and Barrett, 2015]. The probabilities used are typically posterior
probabilities of causal association. Calculating posterior probabilities of causal association require
specification of the causal SNP effect size prior distribution in a Bayesian analysis. This paper
attempts to show how GWAS top hits can be used objectively to inform both the parametric form
of the effect size prior distribution and its parameters.
There are now many fine-mapping methods that require explicit specification of a prior on the
effect sizes. These include single SNP approaches (Wakefield [2009], Spencer et al. [2015], Spencer
et al. [2016]) and multi-SNP methods (Benner et al. [2016]; Boggis et al. [2016]; Pereira et al. [2017];
Guan and Stephens [2011]; Pickrell [2014]; Chen et al. [2015]). The effect size prior is sometimes
taken to be normally distributed, β ∼ N(0, w), for some value of w. For example, w = 0.1 in
Pickrell [2014], whilst w is partly user-supplied and partly determined by case/control numbers in
both FINEMAP [Benner et al., 2016] and CAVIARBF [Chen et al., 2015]). In other approaches
a scale mixture of Normals is used for the effect size prior. For example BIMBAM [Servin and
Stephens, 2007] assumes a prior of the form β ∼ N(0, v/τ), where v is a user-supplied number
and τ has a Gamma distribution (meaning that τ can be integrated out of the joint distribution
of (β, τ)). Other scale mixture distributions are used in Boggis et al. [2016], Pereira et al. [2017]
and Hoggart et al. [2008]. In methods where the value of w is specified, the justification is usually
based on subjective belief about the likely effect size distribution. In the scale mixture of Normal
approaches, the scale mixture distribution is often chosen for computational convenience. It should
be noted that the Laplace prior we are advocating can be represented as a scale mixture of normals
if the the mixture distribution is Exponential with a specific parameter. We feel that a prior
distribution based on observed GWAS top hits is a more objective choice than some of those that
are currently used.
Spencer et al. [2014] considered the Normal distribution for the effect size and demonstrated
that causal SNP Bayes factor ranks are highly sensitive to changes in the prior effect size variance
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even in large studies. It seems reasonable to assume that these ranks will also be sensitive to the
choice of effect size prior distribution. Thus it is highly desirable that putative disease-specific
causal SNP effect sizes that have been identified in GWAS to date are used to inform the effect size
prior distribution in Bayesian fine-mapping studies.
As of 2015, 148 genome-wide significant SNPs (top hits) had so far been identified in breast
cancer [Fachal and Dunning, 2015] with a further 65 identified more recently [Michailidou et al.,
2017]. We base our analysis on the 148 top hits. These top hits do not necessarily represent actual
causal SNPs, but the effect size of the causal SNP tagged by a top hit is likely to be very close to
the effect size of the given top hit. All the top hits so far identified have absolute log odds ratios
above log(1.02). This reflects the lack of statistical power to detect causal SNPs with lower effect
sizes, even for common causal SNPs. This detection threshold needs to be taken into account in
any analysis to determine suitable priors. Another important consideration is the number of SNPs
with smaller effect sizes that are yet-to-discovered. For example in breast cancer it is estimated
that there are 1168 additional loci that harbour disease associated SNPs [Michailidou et al., 2013].
This additional information also provides information about the appropriateness of particular prior
effect size distributions.
In this paper we consider how both GWAS top hits and the hypothesized number of yet-to-be-
discovered SNPs (YTBDS) can be used to inform the effect size prior for use in either fine-mapping
studies or indeed in GWAS. Additionally we allow for uncertainty in the number of YTBDS.
We start by describing the two approaches based on different likelihoods. We then consider the
coverage of confidence intervals for the parameter of the prior distribution using several approaches.
We demonstrate how to choose between the priors using Bayesian model selection and show how to
use all available information relating to GWAS top hits to form a prior on the effect size distribution
parameters that can then be used in Bayesian fine-mapping studies. We consider two priors: the
Normal and Laplace priors. The Normal distribution is widely used in Bayesian fine-mapping
studies [Wakefield, 2008] but the Laplace distribution, which also crucially gives a closed form
Bayes factor when used with a normal likelihood [Wakefield, 2009], provides a better fit to our
breast cancer top hits. This work has important implications for the choice of prior in future
Bayesian fine-mapping studies.
It is important to be clear about the difference between the (non-truncated, non-censored) prior
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on the effect size that is used in a Bayesian fine-mapping study and the (truncated or censored)
prior on the effect size we use in this paper, soley to estimate the prior parameters. For example,
consider a Normal N(0, w) distribution as a prior on the effect size distribution used in a fine-
mapping study. We are interested in using the GWAS top hits to estimate w using either truncated
or censored distributions for the effect sizes. We further determine whether w can justifiably be
assigned a single value or whether there is sufficient uncertainty that it needs to be assigned a
probability distribution. To do this we might put a prior on w, perhaps using expert elicitation
techniques, use the GWAS top hits as our ‘data’ and hence derive a posterior distribution for w.
This posterior distribution for w could then be used as a prior for w in a Bayesian fine-mapping
study. If the posterior is sufficiently concentrated then the posterior mode could be used as a plug
in estimate of the prior parameter.
Materials and Methods
A Normal and Laplace probability distribution are shown in Figure 1 where the variance of the
Laplace and Normal random variables is fixed at 7 × 10−3. To be clear about parameterisations,
we specify the probability density function (PDF) for the Normal and Laplace random variables in
Equations (1) and (2).







w > 0, y ∈ R (1)
Y ∼ La(λ), fY (y) =
λ
2
exp (−λ | y |) λ > 0, y ∈ R (2)
In this paper we are concerned with choosing a suitable prior for the random variable, denoted
by X, representing the effect size (log odds ratio). This prior can then be used as a more objective
prior in fine-mapping studies. it is important, at this point, to distinguish between random variables
X and Y . Y has a standard Laplace or Normal probability distribution whereas X may have a
truncated distribution on some subset of R or some values of X may be censored. We will discuss
approaches to using the GWAS top hits to specify this prior. As can be seen in Figure 1 the Laplace
prior might be a better choice than the Normal distribution when there is a large proportion of
very small odds ratios along with a small number of relatively large ones.
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Maximum likelihood approaches 1 - truncated random variables
Since very small log odds ratios are still mostly undetected due to a lack of power even in GWAS
conducted by large consortia, it seems reasonable to assume that the top hits come from a particular
subset of the real line: X ∈ (−∞, −c]
⋃
[c, ∞) for some positive log odds ratio c (eg c = log(1.02)).





−∞ fY (x; θ) dx
I(| x |> c) (3)
where Y is a non-truncated random variable, as in Equations (1) and (2), θ is its parameter (w or
λ) and I(z) is 1 if z is true and is zero otherwise. If we let F (.) represent the cumulative distribution
function (CDF), then the log-likelihood of x1, . . . , xn (ignoring any constants) is given by
l(θ;x1, x2, ..., xn) =
n∑
i=1
log(fY (xi; θ))− n log(FY (−c; θ)) (4)
The truncated Laplace maximum likelihood estimate (MLE) is λ̂ = n/(
∑n
i=1 |xi|−nc) whilst for the
truncated Normal, calculating the MLE requires numerical approaches (eg the optimize function
in R).
Maximum likelihood approaches 2 - censored random variables
It may be that there are estimates of the number of YTBDS for some diseases. For example in
breast cancer, Fachal et al. [Fachal and Dunning, 2015] estimated that there may be 1000 or
more YTBDS. We can use this information to inform the MLE. We assume that in addition to the
observed top hits we also have an additional m YTBDS. We make the further assumption that these
have low effect size and the concomitant lack of power justifies why they have yet to be discovered.
Of course they could be very rare SNPs with larger effect sizes but very rare SNPs are not the target
of GWAS, since there is never likely to be enough power to detect them even in large consortia
studies. We further assume that all m YTBDS have log odds ratios in a symmetric interval around
zero [−c, c] where c > 0 and is likely to be small. This is akin to standard interval censoring except
that we observe values in the tails, rather than the central region of the distribution. We take c to
be the minimum absolute log odds ratio in the breast cancer top hits which is log(1.02), but note
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that log(1.02) is technically an upper bound for c. The log-likelihood for a single observation x





logfY (x; θ) if | x |≥ c
log(2FY (c; θ)− 1) otherwise
(5)
and the log-likelihood based on observations x1, . . . , xn and m YTBDS is given by
l(θ;x1, x2, ..., xn,m) =
n∑
i=1
log(fY (xi; θ)) +m log(2FY (c ; θ)− 1) (6)
Analytic solutions are not available for the MLEs for this likelihood so we use the optimize function
in R to find the MLE.
Estimating the uncertainty of the MLE
It is appealing to use the MLE as plug-in parameter estimate in the prior in a Bayesian fine-mapping
analysis. In order to assess whether this is appropriate we need to consider the uncertainty in the
MLE. Large uncertainties would make it inappropriate to use the MLE as a plug-in estimate. We
quantify the uncertainty using 95% confidence intervals for the parameter estimates. We calculate
confidence intervals for the parameters in three ways: using observed information and an asymptotic
normal approximation for the MLE, using expected (Fisher) information and an asymptotic normal
approximation for the MLE; using a likelihood interval based on the likelihood ratio test.
The observed information has been shown, based on both empirical and theoretical considera-
tions, to have better coverage properties [Efron and Hinkley, 1978] but this study mostly focussed
on the shape rather than the scale parameter so it is not clear in the cases we consider which has
better properties in practice. The observed information is simpler to calculate since it avoids the
need for integration but the expected information is available in closed for our random variables
(derivations are provided in the Appendix). We consider confidence intervals for four random vari-
ables: the truncated Laplace and Normal random variables and the censored Laplace and Normal
random variables.
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Observed and expected information
The observed information can be used to derive the standard error of the MLE. If l(θ;x1, . . . , xn)
is the log likelihood and θ∗ is the MLE, then the observed information that the data gives about θ
is
J(θ) = − d
2
dθ2




Calculating the observed information is a straightforward exercise in differentiation for all our cases.














For n independent and identically distributed random variables it follows that In(θ) = nI1(θ).
Calculating the expected information is straightforward for the truncated random variables. For
the censored random variables, we adopt the notation and modify the approach of Gertsbakh
[Gertsbakh, 1995].
Let Y be a random variable as defined in either Equations (1) or (2), x be an observed top
hit, h(x, θ) = d
2logfY (x; θ)
dθ2
and q(θ) = d
2log(2FY (c; θ)−1)
dθ2
. After noting that Y |Y ≥ c has density









h(x; θ)fY (x; θ) dx+
∫ ∞
c



























































































(2F − 1) (11)
We calculate the confidence interval in the usual way assuming that the MLE is asymptotically
normal with an expectation equal to the true parameter and variance equal to the reciprocal of the
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information (observed or expected). The calculations for the observed and expected information in
all cases are given in the Appendix.
Likelihood interval
The likelihood interval is based the standard likelihood ratio test. Assume the data consists either
of just the top hits x1, . . . , xn or the top hits plus the number of YTBDS, θ is the parameter
of interest, θ̂n is the MLE of θ which depends on the sample size n, and l is the log-likelihood.
Then standard statistical theory states that, asymptotically, minus twice the difference in the
log likelihood evaluated at the true value of the parameter and the MLE has an asymptotic χ21
distribution. Therefore we can define a 95% likelihood confidence interval as {θ : l(θ; data) >
l(θ̂n; data)− 1.92}.
Model selection
We have so far been concentrating on estimating parameters for various Laplace and Normal random
variables. Perhaps the key question from a practitioner’s perspective is how to choose between
competing prior distributions. One approach is simply to compare the empirical and theoretical
CDFs (see Figures 2 and 3) but to obtain a quantitative measure we adopt a Bayesian model
framework. Let M1 represent the Laplace prior and M2 represent the Normal prior. We will
consider the truncated and censored cases separately. Let Pr(M1) = p, Pr(M2) = 1 − p and
x = x1 . . . , , xn. Then Bayes theorem gives
Pr(M1|x) =
pf(x|M1)







and θ is the parameter for model Mi, π(θ) is the prior on θ (assigned before the top hits are
observed) and f(x|θ) is the likelihood which can be obtained from Equations (4) and (6). Here
p is the prior probability of the Laplace model. The top hits data is used to update this prior
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probability to give the posterior probability of the Laplace model. The posterior probability is
then a function of p and the marginal likelihoods of the Laplace and Gaussian models. So prior
ambivalence about the Laplace versus Gaussian model would be represented by p = 1/2. We
assume a convenient and flexible Ga(η, φ) prior for both w and λ. The Gamma PDF is given
in Equation (14) and this parameterisation is used throughout the paper. We show in the next
section how the hyperparameters η and φ could be elicited. For the truncated Laplace we can


















































For the marginal likelihoods involving a Normal prior we need to use a numerical procedure, eg
Monte Carlo integration to evaluate the integral. The Jeffrey’s prior is appealing as a prior for
scale parameters, and for the truncated Laplace case is easy to derive but is improper (π(λ) ∝ 1/λ)
so isn’t suitable for marginal likelihood calculations. The Jeffrey’s prior doesn’t have a closed-form
for the censored Laplace case so we cannot easily use Jeffrey’s priors for model selection in either
case.
Eliciting priors on λ and w
We put a Ga(η, φ) prior on λ and w and elicit from an expert, two values of the log odds ratios
that enable us to specify values of the hyperparameters η and φ. Let Y be a random variable as
defined in either Equations (1) or (2) and Q represent its 75th percentile (so Q is the median of
the positive log odds ratio). For Y ∼ La(λ) we have that Q = ln2/λ whilst for Y ∼ N(0, w) we
can show that Q =
√
wΦ−1(0.75) where Φ is the CDF of the standard Normal distribution. We
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then elicit values xl and xu such that Pr(Q > xu) = 0.05 and Pr(0 < Q < xl) = 0.05; xl and xu
represent the expert-elicited end points of the central probability region of the 75th percentile. Once
values of xl and xu have been elicited we can obtain λl and λu via λl = ln2/xu and λu = ln2/xl,
and wl and wu via wl = (xl/Φ
−1(0.75))2 and wu = (xu/Φ
−1(0.75))2. To find the hyperparameters
η and φ for the prior on λ we solve the simultaneous equations Pr(λ < λl;λ ∼ Ga(η, φ)) = 0.05
and Pr(λ > λu;λ ∼ Ga(η, φ)) = 0.05 for η and φ. We use the optim function in R to do this.
We do something similar to find η and φ for the Ga(η, φ) prior on w. An alternative approach to
elicitation is simply to use the asymptotic distribution of the MLE as the prior. In this case the
prior would be a Normal distribution with mean equal to the MLE and variance equal to the MLE
variance (often provided by the optimising software used). We provide more details of this in the
results section.
Simulation study
We simulated genotype data between base pairs 201666128 and 201866128 around the CASP8
region on chromosome 2 using Hapgen2 [Su et al., 2011]. We considered two scenarios, both with
a single causal SNP. We simulated 100 data sets for each scenario. In both scenarios we simulated
and analysed the data assuming an additive risk model on the log odds scale. In the first scenario
we simulated 10,000 cases and 10,000 controls with a causal SNP MAF of 0.448 and a simulated
odds ratio of 1.06. In the second scenario we simulated 20,000 cases and 20,000 controls with a
causal SNP MAF of 0.115 and a simulated odds ratio of 1.03. Both of these are relatively small
odds ratios but it is at these smaller odds ratios that we might expect our priors to give a superior
rank to the causal SNP, since the effect size prior variance is estimated assuming many YTBDS
with small odds ratios. We calculated the Wakefield Bayes factors with three values of the effect
size prior variance w. The first value is w = 0.0051 which is based on the top hits data assuming
there are 100 YTBDS (see Table 2); the second value is w = 0.1 which is the default value used in
Pickrell [2014]; the third value is w = 0.04 which is the default value used in SNPTEST2 [Marchini
and Howie, 2010]. For each simulated data set we calculated the mean of the true positive rate at
a set of given false positive rates and plot the results using an ROC curve.
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Results
Simulated coverage using the three confidence interval approximations
We define the unobserved region probability (URP) as FY (c)−FY (−c) for some value c and where
F (.) is the CDF. A small URP implies we observe top hit values close to zero (as for the breast
cancer top hits) whilst a large URP means we only observe values in the tails of the distribution.
The latter might represent GWAS studies still using relatively small numbers of cases and controls
and consequently little power to detect small odds ratios. We assess the coverage (proportion
of confidence intervals containing the true parameter value) when c = log(1.02) in two cases:
w = 0.025, λ = 5 and w = 0.00036 and λ = 61. The first (second) case corresponds to a URP
of 0.1 (0.7). The coverage probability should be 0.95 for a nominal 95% confidence interval. For
the truncated random variables we simply simulate n realisations of X. For the censored random
variables we simulate n realisations of X and then determine the number of YTBDS by solving
n/m = 2FY (−c)/2FY (c)− 1 for m.
The results are shown in Table 1 using 10,000 simulated data sets for each scenario. These
results show that the confidence intervals based on truncated random variables generally have
better coverage properties (coverage probability closer to 0.95) than those based on censored random
variables, for all sample sizes n. For the truncated Laplace the interval based on the likelihood
has good coverage at all values of n whereas the coverage based on the observed and expected
information improves as n increases. For the truncated Normal, when the URP is small, the
coverage is generally close to 0.95 for the likelihood interval for all n and close to 0.95 for the
observed and expected information approach when n is large. For the truncated Normal, when the
URP is 0.7, the coverage properties are considerably worse.
For the censored Laplace the coverage appears close to that expected but is consistently too
high (around 0.96). When the URP is small, the coverage based on the likelihood interval is close
to 0.95 for the censored Normal random variable, but not when the URP is larger. When the URP
is small, the coverage based on the expected information is close to 0.95 for large n for the censored
Normal but intervals based on the observed information have coverage close to 1 in most cases.
These results suggest that the URP is particularly important in determining the coverage prop-
erties of the intervals used, particularly for the censored cases and particularly for the censored
12
Normal case. Likelihood intervals are generally better, in terms of coverage, than those based on
information. For the censored Normal case the expected information sometimes performs better, in
terms of coverage, than the observed information. This is contrary to observations made in other
studies that don’t consider truncated or censored random variables [Efron and Hinkley, 1978].
Graphical assessment of the fit of the top hits to the priors
Using the 148 top hits as the observations and the log-likelihood in Equation (4) we obtain MLEs
ŵ = 0.00693, λ̂ = 18.31 for the truncated random variables. Figure 2 shows the CDF of the Normal
and Laplace priors with these MLEs as well as the empirical CDF of the 148 top hits. The Laplace
prior visually seems to fit the top hits better than the Normal prior. The poor fit around x = 0 is
simply due to slight imbalance in the observed proportion of positive log odds ratios.
We use Equation (6) to estimate λ and w for the censored random variables with various values
of the number YTBDS. Figure 3 shows the CDF of the two possible prior distributions using the
MLEs from Equation (6) as well as the empirical CDF of the 148 top hits. Again we see a better
fit of the top hits to the Laplace prior than to the Normal prior.
MLEs based on the top hits
Table 2 shoes the MLE and the 95% confidence interval for the parameters for the truncated and
censored Laplace and Normal random variables using the 148 breast cancer top hits. For the
censored case the number of YTBDS was varied between 100 and 1000. We used different methods
for constructing the intervals depending on which method gave the most reliable results in Table
1. It is clear from Table 2 that the parameter estimates are very sensitive to the estimated number
of YTBDS. Generally the number of YTBDS is not known with much certainty. The maximum
likelihood approaches considered do not easily allow this uncertainty to be incorporated in to
parameter estimation. As a result we advocate a Bayesian approach that naturally accommodates
this uncertatinty.
Results of the simulation experiment
In the Materials and Methods section we described a simulation study to assess the causal SNP
ranks, based on Wakefield Bayes factors, using our prior based on the top hits data and two other
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values of the effect size prior variance. The results are shown in the ROC curves in Figure 4. For
these parameter settings, our method of informing the effect size prior variance using the top hits
data gives superior performance compared to the two default values used in Pickrell [2014] and
SNPTEST2 [Marchini and Howie, 2010].
Using the top hits to choose between competing priors for the effect sizes
Suppose we use the previously described elicitation approach and elicit xl = log(1.005) and xu =
log(1.12) representing prior belief that the log odds ratios of breast cancer causal SNPs are relatively
small. These values give λ ∼ Ga(1.49, 0.028) and w ∼ Ga(0.564, 73.5). Using these priors we
consider the effect of sample size on the posterior probabilities of the models by taking the n top
hits with largest absolute values (the n values furthest from 0). We take c as the minimum of the
absolute values of the elements of these n values. Smaller numbers of top hits are what you might
expect in GWAS studies of smaller size and in diseases less well studied than breast cancer. In
these cases there will be fewer genome-wide significant GWAS top hits and larger effect sizes will
be discovered first. We consider n = 10, 50, 100 and 148 where 148 is the total number of available
breast cancer top hits. We also considered what happens in the case where the elicited values of
the 75th percentile of the log odds ratio are xl = log(1.05) and xu = log(1.20) representing prior
belief that the log odds ratios of breast cancer causal SNPs are relatively large. The corresponding
priors on λ and w are shown in Figure 5. The posterior probabilities of the laplace model, using
truncated random variables, are shown in Table 3.
Regardless of whether the prior belief is for relatively small or large log odds ratios we find
overwhelming evidence in favour of the Laplace model with n ≥ 50 with posterior probabilities
exceeding 0.99 in all cases. For n = 10 the posterior probabilities drops to around 0.60 but still
show more support for the Laplace than the Normal prior.
Table 3 shows the posterior probabilities of the laplace model, using censored random variables.
We see that the number of YTBDS has more of an impact on the posterior probability of the
Laplace model than the number of observed top hits. When there are 10 YTBDS there is very
strong support for the Normal prior, with 50 YTBDS the evidence is equivocal with generally more
support for the Laplace prior. When there are 100 or more YTBDS the support for the Laplace is
very strong. We don’t consider m > 100 since the posterior probability in nearly all cases is close
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to one.
Prior construction using GWAS top hits for the Laplace prior
The numbers in Table 3 show overwhelming support for the Laplace prior when n = 148 and m is
fifty or more, which is believed to be the case in breast cancer (m ≈ 1000). As a result we only
consider the Laplace prior hereafter. We assume a λ ∼ Ga(η = 1.5, φ = 0.028) prior that has strong
support for smaller odds ratios (as used in Table 3). Using Equation (3) we get a truncated Laplace
likelihood based on n top hits x1, . . . , xn which is proportional to λ
n exp(−λ(∑ |xi| − nc)). The
posterior distribution of λ is therefore a gamma distribution λ|x1, . . . , xn ∼ Ga(n+η,
∑
|xi|−nc+φ).
Figure 6(a) shows the posterior distribution for n = 25, 75 and 148. The posterior mode here is
(n + η − 1)/(
∑
|xi| − nc + φ) which, with η = 1.488 and φ = 0.0285, is very close to the MLE
given by n/(
∑
|xi| − nc) for all values of n considered. Similarly the MLE variance given by
n/(
∑n
i=1 |xi| − nc)2 and posterior variance given by (n+ η)/(
∑n
i=1 |xi| − nc+ φ)2 are quite similar
for all n so, assuming a truncated random variable for the log odds ratio, a sensible approach is
simply to use the Normal distribution of the MLE as a prior for λ in fine-mapping (even when n is
small). Alternatively, given the relatively small posterior variance it is also reasonable to use the
MLE as a plug in estimate for λ in the Bayes factor calculation (whilst checking the sensitivity of
the Bayes factor to using other plausible values of λ indicated by the posterior).
Using knowledge of the number of YTBDS to inform the prior
Assuming a λ ∼ Ga(η = 1.5, φ = 0.028) prior we can derive a closed form expression for the
posterior distribution. The prior and likelihood are given in Equations (14) - (16) and the marginal
likelihood in Equation (17) and so, after a little algebra, we find that the posterior probability
density is given by




where Qi ∼ Ga(n+ η, hi), hi =
∑n



















The posterior distribution is an alternating sign mixture of gamma random variables.
Figure 6(b) shows the posterior distributions obtained with varying number of YTBDS (m=100,
250, 500 and 1000). The 95% credible intervals in Figure 6(b) and the 95% confidence intervals
based on the MLEs in Table 2 are very similar so we conclude that the prior is highly uninformative.
Again we could use the asymptotic distribution of the MLE rather than the posterior distribution
as a fine-mapping prior for the effect size. However this is only possible if there is certainty in
the number of YTBDS. This is quite unlikely and so we need to be able to take account of the
uncertainty in the number of YTBDS. If M is the random variable representing the number of
YTBDS then using the notation of Equations (18) and (19) we have







In breast cancer we believe there may be around 1000 additional loci but there is considerable
uncertainty in this number so we choose two different Beta-Binomial(α, β) priors onM with support
m ∈ [0, 2000] with parameters α = 11, β = 4 giving a negatively skewed prior and α = 7, β = 7
giving a prior for m symmetric around m = 1000. These two priors for m are shown in Figure
7(a). Figure 7(b) shows both the prior distribution on λ and the posterior distributions on λ for
both of the BetaBinomial prior distributions on m. How these derived posteriors might be used in
practice again depends on the variance. A small variance implies that using a point estimate for λ
may be justified, with some checks on the sensitivity to small changes. The variance observed in
Figure 6(b) suggests that using the posterior mode, mean or median in breast cancer may not be
appropriate. Ideally we would take the results of Figure 6(b) as the prior for the parameter in a
Bayesian fine-mapping study, but a Normal or Gamma distribution approximation may also be a
sensible compromise.
R libraries




In this paper we show how GWAS top hits can be used, in addition to estimates of the number of
YTBDS if they are available, to choose between competing causal SNP effect size prior distributions.
We show how likelihood-based approaches can be used to estimate the parameters of these effect
size distributions and how the uncertainty in the parameter estimates can be quantified. We also
demonstrate how the uncertainty in the number of YTBDS can be accommodated. We show that
for the breast cancer GWAS top hits, the Laplace distribution convincingly provides a better fit
compared with the Normal distribution which is the default prior distribution in Bayesian fine-
mapping association studies.
Even with 148 breast cancer GWAS top hits there is still considerable uncertainty in the pos-
terior distribution of λ which in part results from the uncertainty put on the number of YTBDS.
It is clear that the estimates of λ can change substantially when the number of YTBDS is taken
into account. This suggest that caution needs to be applied when using an estimate of the number
of YTBDS and that the uncertainty in the number of YTBDS must be fully taken into account.
At the very least this paper shows how GWAS top hits can be used to obtain MLEs of the scale
parameter of the effect size prior along with a confidence interval.
In current fine-mapping studies the parameters (λ or w) are either given default values or
subjective elicitation is used to find the value that best fits the expert’s beliefs. Our framework
provides a way to use the elicitation process to instead elicit a prior distribution on λ and then
update this distribution using the top hits to give a posterior distribution that could then be used
as a fine-mapping prior.
In a univariate fine-mapping study it is straightforward to calculate the Bayes factor with a
prior on the parameter of the effect size distribution. This could be done simply by Monte Carlo
integration, which has well understood and guaranteed asymptotic convergence properties. In a
multivariate model selection approach that enumerates over possible models, such as that used in
FINEMAP [Benner et al., 2016], putting a prior on the parameter of the effect size distribution
would lead to intractable marginal likelihoods. Calculating these marginal likelihoods by say Monte
Carlo integration is not computationally feasible due to the number of possible models that need
to be enumerated. In this case the best that could possibly be done is to use the posterior mode or
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median as a point estimate of the hyperparameter. A sensitivity analysis should then be undertaken
to assess the effect of small changes in the parameter value on the posterior probability of causal
association for each SNP.
We have derived closed form expressions for the posterior distributions on λ for the Laplace
prior but these do not exist for the Normal prior. Instead it would be necessary to do some sort
of posterior sampling, for example via Metropolis-Hastings. This is another clear advantage of the
Laplace prior over the Normal prior on the effect sizes.
A potential weakness of this approach is the assumption that GWAS top hits are all causal SNPs
or in strong linkage disequilibrium with causal SNPs. To us this seems a reasonable assumption.
If not, it seems reasonable to assume that the probability that a top hit is not causal is likely to
the same for each top hit, and not related to the top hit effect size. So if the truely causal SNPs
are a subset of the top hits then at least they are a random subset.
The aim of this paper is to bring to the attention of practitioners the fact that genome-wide
significant GWAS top hits, even in very small number, can be highly informative about the scale
parameters of the causal SNP effect size prior distribution which are currently often specified in
ad hoc ways. Using more objective data-driven approaches described in this paper ameliorate
the criticisms about using completely subjective elicited priors. Additional information about
the number of YTBDS can also provide much information about the prior parameters but the
uncertainties in the estimates of the number of YTBDS must be carefully taken into account.
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Information for the truncated Laplace distribution
From Equations (2) and (4) the log-likelihood is








and both the observed and expected information are therefore given by In(λ) = J(λ) = nλ
−2
Information for the truncated Normal distribution
Let v = c/
√
(w), φ(.) represent the standard Normal PDF and Φ(.) represent the standard Normal




































(v2 − 3)Φ(−v)− vφ(v)
)
. (24)

















































where fX(xi;w) is given in Equation (3) and we have used the standard result for
∫
u2φ(u)du




















Information for the censored Laplace distribution







Using Equation (11), we need expressions for f
′
Y (x;λ)
2/fY (x;λ) and F
′
Y (c;λ) where fY (x;λ) is












































Information for the censored Normal distribution
Assuming that x1, . . . , xn are observed and there are m censored observations, Equation (6) gives
the log likelihood as




























2vφ(v) + (v2 − 3)(2Φ(v)− 1)
]
(35)
Using Equation (11), we need expressions for f
′
Y (x;w)
2/fY (x;w) and F
′









and then using the standard result for
∫
















2− 2Φ(v) + v(1 + v2)φ(v)
]
(37)






w2(2Φ(v)− 1) . (38)















Figure 1: Probability density of a Normal and Laplace random variable both with a variance of
0.007 and an expectation of zero.
Figure 2: Empirical CDF of the top hits and the theoretical CDFs of the Normal and Laplace
distributions with the parameters taken to be the maximum likelihood estimates from a likelihood
based on truncated random variables.
Figure 3: Empirical CDF of the top hits and theoretical CDFs of the Normal and Laplace distri-
butions with the parameter taken to be the maximum likelihood estimates from a likelihood based
on censored random variables for various values of the number of YTBDS (m).
Figure 4: ROC curves comparing the ranking performance of Wakefield Bayes factors with a
β ∼ N(0, w) effect size prior for three values of w: w = 0.0051, based on the top hits data
assuming there are 100 YTBDS; w = 0.1, the default value used in Pickrell [2014]; w = 0.04, the
default value used in SNPTEST2 [Marchini and Howie, 2010]. The top row shows the whole false
positive range. The bottom row shows false positive values below 0.2. The left hand plots show
the results for a single causal SNP with a MAF of 0.448 and an odds ratio of 1.03 with 20,000 cases
and 20,000 controls. The right hand plots show the results for a single causal SNP with a MAF
of 0.115 and an odds ratio of 1.06 with 10,000 cases and 10,000 controls. A hundred data sets are
used in each scenario.
Figure 5 main: Gamma(η, φ) prior distributions on λ and w used in model comparison. In both
plots two priors are shown, one representing strong support for small odds ratios, the other for
strong support for larger odds ratios.
Figure 5a: Gamma prior distributions on λ.
Figure 5b: Gamma prior distributions on w.
Figure 6 main: Posterior distributions on λ with likelihoods based on a) truncated random variables
and b) censored random variables. The prior is λ ∼ Ga(η = 1.5, φ = 0.028) in both plots.
Figure 6a: Posterior distributions on λ as functions of the number of top hits available (n).
Figure 6b: Posterior distributions on λ by number of YTBDS (m) using the information from all
n = 148 top hits.
Figure 7 main: Various priors on m and λ and posteriors on λ based on different priors on m.
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Figure 7a: Two Beta-Binomial priors on m allowing uncertainty around the most likely value of
m = 1000.




URP = 0.1 URP = 0.7
Truncated Censored Truncated Censored
La(λ) N(0,w) La(λ) N(0,w) La(λ) N(0,w) La(λ) N(0,w)
Observed 0.950 0.945 0.960 1.000 0.950 0.975 0.960 0.917
n=200 Expected 0.950 0.945 0.960 0.952 0.950 0.978 0.960 0.909
Likelihood 0.949 0.949 0.960 0.956 0.949 0.914 0.960 0.997
Observed 0.951 0.940 0.961 1.000 0.950 0.970 0.961 0.999
n=50 Expected 0.951 0.931 0.962 0.939 0.950 0.968 0.961 0.996
Likelihood 0.950 0.950 0.961 0.956 0.950 0.887 0.960 0.980
Observed 0.953 0.914 0.962 0.999 0.961 0.898 0.963 1.000
n=10 Expected 0.955 0.872 0.963 0.883 0.961 0.861 0.963 0.997
Likelihood 0.948 0.947 0.961 0.955 0.947 0.945 0.962 0.999
Table 1. Coverage of 95% confidence intervals for Normal and Laplace parameters for truncated
and censored random variables where c = log(1.02) and the number of top hits is 10, 50 and 200.
Three methods for constructing the intervals are considered based on: observed information,
expected information and the likelihood interval. In columns 3 - 6, w = 0.025 and λ = 5 which
give a small unobserved region probability (URP) of 0.1. In columns 7 - 10, w = 0.00036 and
λ = 61 which gives a large URP of 0.7
Laplace(λ) N(0,w)
Type number of yet-to-be λ̂ 95% CI ŵ 95% CI
discovered SNPs ×10−5 ×10−5
Truncated NA 18.3 (15.4, 21.3) 692 (559,867)
Censored 100 20.8 (18.2, 23.4) 510 (430,615)
Censored 250 30.1 (27.1, 33.0) 326 (286,374)
Censored 500 42.4 (39.1, 45.6) 202 (183,226)
Censored 1000 60.5 (56.8, 64.2) 121 (113,130)
Table 2. MLEs and 95% confidence intervals for Normal and Laplace parameters for truncated
and censored random variables based on the 148 breast cancer top hits and variable numbers of
YTBDS for the censored case.
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Posterior probability of Laplace(λ) prior
Prior support for smaller effect sizes Prior support for larger effect sizes
(xl = 1.005, xu = 1.120) (xl = 1.050, xu = 1.200)
Number of truncated censored likelihood truncated censored likelihood
top hits likelihood likelihood
m = 10 m = 50 m = 100 m = 10 m = 50 m = 100
148 1.0 1.8× 10−3 1.0 1.0 1.0 4.8× 10−3 1.0 1.0
100 1.0 9.9× 10−5 0.31 1.0 1.0 4.3× 10−4 0.50 1.0
50 1.0 1.4× 10−3 0.51 1.0 0.99 5.5× 10−3 0.74 1.0
10 0.64 0.12 0.60 0.95 0.60 0.19 0.78 0.96
Table 3. Posterior probabilities, using the censored likelihood, for the Laplace prior where the
number of top hits (n) varies between 10 and 148, the number of YTBDS (m) varies between 10
and 100. Two scenarios are considered: prior belief in smaller log odds ratios and prior belief in
larger log odds ratios.
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Ga(θ= 1.49, φ= 0.0281)
Ga(θ= 6.64, φ= 0.801)
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Ga(θ= 0.563, φ= 73.5)
Ga(θ= 1.94, φ= 63.7)
(b)
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